- In the past week, Revvity, Inc. reported second-quarter 2026 results with sales of US$729.69 million, net income of US$51.82 million, modestly higher diluted EPS, reaffirmed a regular US$0.07 quarterly dividend, and issued full-year 2026 pro forma revenue guidance of US$2.83 billion to US$2.86 billion.
- Management linked these updates to improving pharma and biotech demand, strong Diagnostics performance, and ongoing progress exiting its China immunodiagnostics business to focus on higher-margin areas.
- Next, we’ll examine how Revvity’s raised full-year revenue guidance and Diagnostics momentum reshape the company’s broader investment narrative.
Find 50 companies with promising cash flow potential yet trading below their fair value.
Revvity Investment Narrative Recap
To own Revvity, you need to believe it can steadily build a higher-margin mix around Diagnostics and software while managing policy and funding headwinds. The latest quarter and reaffirmed dividend support that narrative, but the key near-term catalyst remains sustained Diagnostics strength, and the biggest risk is continued pricing and regulatory pressure in healthcare and China. The new guidance does not remove that risk, but it does not materially increase it either.
The fresh full-year 2026 pro forma revenue outlook of US$2.83 billion to US$2.86 billion is the most relevant new data point here. It matters because it ties directly into the story that higher-margin Diagnostics and software can support organic growth even as Revvity exits China immunodiagnostics, a move that may reduce exposure to some of the reimbursement and regulatory uncertainties highlighted in the current risk set.
But while revenue guidance has ticked higher, investors should still pay close attention to how policy changes and pricing pressure could affect Diagnostics profitability and...
Read the full narrative on Revvity (it's free!)
Revvity’s narrative projects $3.4 billion revenue and $554.4 million earnings by 2029. This requires 4.9% yearly revenue growth and about a $317 million earnings increase from $237.4 million today.
Uncover how Revvity's forecasts yield a $121.07 fair value, a 6% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming Revvity could reach about US$3.3 billion in revenue and US$456.8 million in earnings, yet this new guidance and the ongoing China Diagnostics overhang could either support that optimism or make those forecasts look stretched, depending on how you weigh the regulatory risk in Diagnostics against the potential upside from software and automation.
Explore 3 other fair value estimates on Revvity - why the stock might be worth as much as 35% more than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Revvity research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Revvity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Revvity's overall financial health at a glance.
Seeking Other Investments?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com